Table 1.
CHIKV Vaccine Strategies
| Vaccine | Platform | Dosing Scheme |
Stage of Development | Year of Original Description | References |
|---|---|---|---|---|---|
| 167 Inactivated | Inactivated | Multi-Dose | Phase I | 1971 |
Harrison 1971 White 1972 |
| 181/25 | Live Attenuated | Single Dose | Phase II | 1986 |
Levitt 1986 Turell 1992 McClain 1998 Edelman 2000 Gorchakov 2012 |
| Consensus Capsid DNA |
DNA | Multi-Dose | Pre-Clinical | 2008 | Muthumani 2008 |
| ECSA Based Inactivated |
Inactivated | Multi-Dose | Pre-Clinical | 2009 | Tiwari 2009 |
| VSV/CHIKV VLP | VLP | Multi-Dose | Phase I | 2010 |
Akahata 2010 Chang 2014 |
| Structural Gene DNA | DNA | Multi-Dose | Pre-Clinical | 2011 | Mallilankaraman 2011 |
| Adenovirus Chimera | Chimeric | Single Dose | Pre-Clinical | 2011 | Wang 2011 |
| Insect Cell VLP | VLP | Single Dose | Pre-Clinical | 2011 |
Metz 2011 Metz 2013 |
| CHIKV/IRES | Live Attenuated | Single Dose | Pre-Clinical | 2011 |
Plante 2011 Partidos 2011 Partidos 2012 Roy 2014 Plante 2015 |
| Alphavirus Chimera | Chimeric | Single Dose | Pre-Clinical | 2011 | Wang 2011 |
| E2 Protein | Subunit | Multi-Dose | Pre-Clinical | 2012 | Kumar 2012 |
| MV/CHIKV VLP | VLP | Multi-Dose | Phase I | 2013 |
Brandler 2013 Ramsauer 2015 |